Summary："Breakthrough Lung Cancer Treatment Results Revealed in Groundbreaking ASCO Study Findings"CHENGDU,

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"Breakthrough Lung Cancer Treatment Results Revealed in Groundbreaking ASCO Study Findings"

CHENGDU, China, May 29, 2026 /PRNewswire/ -- A major breakthrough in lung cancer treatment has been achieved with the release of a pivotal Phase III clinical trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced the groundbreaking results, marking a significant milestone in the fight against one of the world's deadliest cancers.

The study findings, presented at the prestigious ASCO gathering, demonstrated a substantial improvement in overall survival rates among patients treated with the Company's innovative therapy. This novel treatment, designed to target specific genetic mutations driving lung cancer progression, has shown remarkable efficacy and safety in the clinical trial. The results have generated considerable excitement within the oncology community, with many experts hailing the development as a potential game-changer in lung cancer treatment.

The successful outcome of this trial is a testament to the Company's commitment to advancing cancer care through cutting-edge research and development. As the global lung cancer treatment landscape continues to evolve, this breakthrough is poised to have a profound impact on patient outcomes and industry trends. Analysts predict that the therapy, upon approval, could capture a significant share of the lung cancer treatment market, driving growth and innovation in the sector.

As the oncology community continues to dissect the study's findings, expectations are high that this pioneering treatment will soon become a new standard of care for lung cancer patients. With regulatory submissions underway, the Company is on track to bring this life-changing therapy to market, offering new hope to patients and families affected by this devastating disease. The implications of this breakthrough extend beyond the Company's success, as it underscores the potential for continued advancements in targeted cancer therapies.

In conclusion, the ASCO study findings represent a major leap forward in the treatment of lung cancer, highlighting the power of innovative research and collaboration in the pursuit of improved patient outcomes. As the Company moves forward with regulatory approvals and commercialization, the oncology community and patients worldwide eagerly await the potential benefits of this groundbreaking therapy.